Hydroxychlorquine and Azythromycine Combination Treatment for COVID-19 Can Raise Risk for Dangerous Abnormal Heart Rhythms
Cardiologists from Oregon Health & Science University and Indiana University recommend clinicians who treat COVID-19 patients with the malaria-antibiotic drug combination hydroxychloroquine and azithromycin also consider monitoring those patients for ventricular arrhythmia, which involves the lower heart chambers beating quickly and irregularly and can lead to cardiac arrest.
The guidance was published this week in the American College of Cardiology publication Cardiology Magazine.
There are hundreds of drugs that can increase the risk for cardiac arrest, but using two together in patients who are already at risk or critically ill could increase that risk further, the paper notes.
“While there is yet very little data regarding hydroxychloroquine and azithromycin’s effectiveness as a treatment for COVID-19, some clinicians are considering combining them during this global pandemic,” said the paper’s lead author, Eric Stecker, M.D., M.P.H., an associate professor of medicine (cardiovascular medicine) in the OHSU School of Medicine and OHSU Knight Cardiovascular Institute. “If physicians use their best medical judgement and order this drug combination for coronavirus patients, we want them to be aware of potential adverse side effects.”
Stecker and colleagues recommend clinicians who treat COVID-19 patients with the drug combination also monitor patients for dangerous arrhythmias. However, they acknowledge limited resources could make monitoring a challenge.
Timothy F. Simpson, Richard J. Kovacs, Eric C. Stecker, Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19. Cardiology Magazine, March 29, 2020
This information is not intended as medical advice or clinician guidance. This content contains edited excerpts to bring attention to the work of the researchers and study authors. Please support their efforts and click through for the full context.
